Amgen Selects Veeva Vault CRM for Global Deployment

Zacks Investment Research··US·Read original
3▲1 ▼1Impact / 5
Summary · why it matters

Amgen has selected Veeva Systems' Vault CRM for a global deployment, extending a collaboration that has spanned more than a decade. The rollout is expected to support Amgen's commercial operations as it advances new therapies across worldwide markets, with Amgen saying the migration will help accelerate delivery of new therapies with greater speed and agility. The win reinforces Veeva's commercial business, where management recently described fiscal second-quarter 2027 as its best CRM quarter ever, with commercial subscription revenue growing about 13% year over year. Vault CRM now has more than 180 live customers, and management reiterated confidence in maintaining more than 70% market share in life sciences CRM. Veeva currently has a market capitalization of $42.13 billion, and its shares have gained 16.8% year to date.

Impact on assets 5

Biotech & Genomic Medicine▲ · 2 stocks
Amgen Inc
AMGN
± MixedDemandrelevance

Amgen selected Veeva Vault CRM for global deployment to support its commercial operations, a software adoption rather than a product-demand event for Amgen itself.

Cloud & Digital Infrastructure▲ · 1 stocks
Veeva Systems Inc Class A
VEEV
▲ PositiveDemandrelevance

Amgen selected Veeva's Vault CRM for a global deployment, a concrete customer win extending a decade-long collaboration.

Artificial Intelligence▼ · 1 stocks
Salesforce.com Inc
CRM
▼ NegativeCompetitionrelevance

Amgen's selection of Veeva Vault CRM is a competitive loss for Salesforce in life-sciences CRM, though Salesforce is not named in the article.

Robotics & Physical AI▲ · 1 stocks
© 2026 MarketIVNews